New hope against a deadly parasitic disease: LXE408 trial shows promise
NCT ID NCT05957978
First seen Jan 09, 2026 · Last updated May 08, 2026 · Updated 16 times
Summary
This study tested a new drug called LXE408 for people with primary visceral leishmaniasis, a serious parasitic disease common in Ethiopia. 52 adults took part, and researchers checked if the drug could clear the parasite and improve symptoms by day 28. The goal was to see if LXE408 works as well as the current standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY VISCERAL LEISHMANIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Gondar
Gonder, Ethiopia
Conditions
Explore the condition pages connected to this study.